Stryker will pay approximately $701 million for NOVADAQ Technologies, a Canadian maker of fluorescent imaging technology for blood flow visualization, in a definitive deal that represents a 96% premium on NOVADAQ's closing share price on June 16. The acquisition, which is expected to be completed at the end of the third quarter, is subject to approval by NOVADAQ shareholders and other customary closing conditions.
Massachusetts-based scientific instruments maker PerkinElmer reached a deal to acquire German medical diagnostics company Euroimmun Medical Laboratory Diagnostics AG for $1.3 billion in cash. The acquisition, which is expected to be completed in the fourth quarter, will allow PerkinElmer to expand into autoimmune, infectious disease and allergy diagnostic markets.
OpGen and Thermo Fisher Scientific have reached a supply agreement to commercialize OpGen's Acuitas Rapid Test for Pathogen ID in combination with Thermo Fisher's new mid-throughput real-time PCR system. OpGen disclosed no further terms of the deal, nor which Thermo Fisher system is part of the agreement.
Mazor Robotics appointed Oren Zarchin to lead its newly created Product Development Group and Eli Zehavi to head its newly established Advanced Technology Group. The company has also given additional roles to Christopher Prentice, CEO of its US subsidiary, as chief commercial officer, and to Chief Financial Officer Sharon Levita as vice president of business operations; Joshua Belkar has also been tapped to serve as vice president of operations and service.
Bob Cathcart has been tapped to serve as CEO of Johns Hopkins spinout Clear Guide Medical. Cathcart, who most recently served as an executive at Hansen Medical, replaces Dorothee Heisenberg, who will become executive vice president.
A wireless, battery-free pacemaker has shown success in powering the heart in pig models, according to researchers from Rice University and the Texas Heart Institute. The pacemaker, designed by lead researcher Aydin Babakhani, gets its energy wirelessly from radio frequency radiation transmitted from an external battery pack a few centimeters away. The implantable chip is less than 4 mm wide and uses a receiving antenna, an AC-to-DC rectifier, a power management unit and a pacing activation signal. Read the story.
A 30-patient study by the Canadian Radiostereometric Analysis Network showed stable fixation in knee replacement with the tibial base of the Attune system from Johnson & Johnson subsidiary DePuy Synthes. Over two years, the tibial base migrated an average of 0.02 mm in the superior-inferior direction, with an average maximum total point motion of 0.21 mm and average micromotion of 0.17 mm, according to results presented at the Canadian Orthopaedic Association's annual meeting.
A scientific agreement between MDxHealth and QUT bluebox, the Queensland University of Technology's commercialization arm, will evaluate and develop a liquid biopsy epigenetic assay for early oral cancer detection. Under the deal, the first licensing option for commercial diagnostic rights will go to MDxHealth; proceeds will be used for research and translational activities at the university and MDxHealth's urologic cancer diagnostics research and development pipeline.
Meditech Spine obtained clearance from the FDA for its Talos Lumbar (HA) Peek IBF, an intervertebral body device for patients with lumbar degenerative disc disease who have up to grade 1 spondylolisthesis at one or two contiguous levels from L2 to S1. The device may be used with autograft or allograft composed of corticocancellous or cancellous bone graft.
The FDA would require appropriations worth $1.2 billion from 2018 to 2022 to implement changes in the Senate's user fee reauthorization bill, according to a cost estimate released by the Congressional Budget Office. Medical device program changes that would be implemented under the bill would add $243 million to the FDA's costs and require the agency to add at least 200 full-time-equivalent positions, the CBO said.
Massachusetts Gov. Charlie Baker is expected to unveil this week a proposal for a five-year, $500 million life sciences initiative focused on medtech and biotech companies. The initiative would include capital spending worth up to $295 million and tax incentives worth up to $150 million for companies that provide new jobs.
June 27-28 | Washington, D.C. During this workshop, you will be provided with the roadmap and practical applications to successfully navigate the many potential reimbursement pitfalls. After an overview of current reimbursement issues, you'll hear from industry veterans and reimbursement professionals who will discuss case studies and real-life scenarios. Learn more.
The AdvaMed Purchasing Group is a new member-only benefit that helps companies purchase the very best goods and services from nationally recognized suppliers at the very best cost, using a trusted and proven vetting system and the collective purchasing power of our membership. Participation is free for AdvaMed members, and there are no minimum commitments. Get started today.